Bayer AG NA

2021 Q2–Q3

Bayer posted an additional gross provision of USD 4.5 billion in Q2 2021 to reflect potential long-term Roundup exposure and announced measures to manage litigation, including withdrawal of glyphosate-based Roundup from the U.S. residential market starting in 2023. A federal judge rejected Bayer's proposed USD 2.0 billion settlement for future Roundup claims in May 2021. [8], [10]

Investors viewed litigation as the primary constraint on valuation. The provision and product withdrawal signaled pragmatic risk management, though a substantial binary liability remained on the balance sheet. [8]

The share price entered an extended drawdown with elevated volatility as legal uncertainty capped upside potential.

FY 2021 (reported early 2022)

Bayer reported operational recovery with Group sales of €44.08bn and core EPS of €6.51, alongside recovering free cash flow and improving net financial debt. [12], [17]

Market sentiment became mixed: Crop Science strength supported a recovery narrative, but unresolved U.S. litigation continued to limit valuation multiples. [12]

The share price recovered from pandemic lows but gains remained capped by the litigation overhang.

June 2022

The U.S. Supreme Court declined to hear Bayer/Monsanto appeals in the Hardeman (June 21) and Pilliod (June 27) cases, leaving multimillion-dollar jury awards intact and preserving substantial litigation exposure. [21], [22], [24]

Investor sentiment deteriorated as the path to quick legal resolution narrowed and potential liability remained large and uncertain. [21]

The share price experienced a renewed sell-off with elevated volatility.

FY 2022 (reported Feb 2023)

Bayer delivered strong operational results: Group sales of €50.739bn and EBITDA before special items of €13.513bn. Crop Science posted record sales of approximately €25.17bn with materially higher EBITDA; core EPS rose to approximately €7.94. [33], [34], [39], [40]

Investors briefly re-rated Bayer toward an operational growth narrative driven by Crop Science outperformance, though litigation remained a downside tail risk. [33], [40]

The share price rallied as operational beats partially offset legal concerns.

Feb–Jun 2023 (governance reset)

Bayer announced Bill Anderson (ex-Roche pharma) as CEO, joining the Board on April 1 and assuming the CEO role from June 1, 2023. Werner Baumann retired at the end of May 2023 following sustained investor pressure for leadership change. [47], [49], [52], [61]

Investor perception shifted toward governance and strategy reset — expectations focused on accelerated restructuring, cost cuts and portfolio review, including possible divestments or break-up scenarios. [47], [48], [60]

The share price experienced short-term relief on the governance reset announcement, though the market awaited concrete execution.

H2 2023 – FY 2023 (reported 2024)

Crop Science earnings weakened with notably lower glyphosate prices and volumes. Q3 2023 results fell below prior year with Crop Science EBITDA sharply lower. FY2023 Group sales declined to €47.637bn and EBITDA before special items to €11.706bn. [45], [37], [44]

Market optimism cooled as 2022 strength appeared partly cyclical. Investors refocused on margin resilience, structural fixes and whether management would pursue concrete portfolio moves. [45], [48], [60]

The share price entered a downtrend into consolidation with elevated volatility as earnings softened.

30 Sep 2025 (provisions baseline reported in 2026 disclosure)

Bayer/Monsanto reported litigation provisions and liabilities of €7.8bn as of 30 September 2025, including €6.5bn for glyphosate, establishing the baseline cited ahead of further negotiations. [5]

Markets treated the reported provisions as material but finite. Valuation remained sensitive to whether a negotiated global solution would resolve remaining exposure. [5]

The share price remained range-bound with event-driven spikes expected around settlement news or court rulings.

17 Feb 2026

Monsanto announced a proposed U.S. nationwide class settlement to resolve current and future Roundup claims, funded by declining capped annual payments totaling up to USD 7.25bn over up to 21 years. Bayer stated the deal would increase litigation provisions and liabilities to approximately €11.8bn, including approximately €9.6bn for glyphosate, subject to approvals and audit. [5]

Market reaction was cautiously positive — the proposal represented major progress toward de-risking the balance sheet, though investor conviction was tempered pending judicial approval and implementation details. [5]

The share price experienced an initial relief rally followed by choppy trading as investors awaited court outcomes.

17 Jun 2026

A U.S. federal judge remanded the proposed USD 7.25bn settlement back to the Missouri state court that had fast-tracked approval, declining federal oversight and reintroducing procedural uncertainty. [7]

The remand reintroduced near-term legal risk and procedural uncertainty. Investors re-priced the deal as non-final and resumed a cautious stance. [7]

The share price experienced renewed volatility and pullbacks on the legal reversal.

11 Jul 2026 (current)

Bayer (BAYN.XETRA) share price stands at 50.12.

The market price reflects the balance between demonstrated operational earnings power (Crop Science peak in 2022) and cyclical headwinds plus margin pressure since 2023, offset against residual but narrowing multi-year litigation uncertainty as settlement negotiations and court reviews continue. [33], [45], [5], [7]

Primary near-term catalysts are final court approval or rejection of the proposed Roundup resolution and clear, tangible portfolio or strategic actions from management.